Skip to content

Study · Non-randomized trial · n = 28 · 1996

3 results

Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.

Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, Melis GB

Fertility and sterility1 Apr 1996Cited by 44 (Europe PMC)

PMID8654625 (opens in a new tab)DOI10.1016/s0015-0282(16)58200-4 (opens in a new tab)PepBankPUB-08654625
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In women with endometriosis, lumbar bone mineral density significantly decreased after 6 months of goserelin.

    In plain wordsLumbar bone density decreased after 6 months of goserelin in women with endometriosis.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar bone mineral density after treatment
    Study

    n = 28

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days, six implants · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Lumbar bone mineral density values significantly decreased after 6 months of GnRH-a treatment.
    2 context sentences
    Summary · context
    Controlled clinical study in volunteer women.
    Summary · context
    Twenty-eight women (mean age +/- SE 81.1 +/- 0.99 years) with endometriosis diagnosed by laparoscopy and 25 healthy, normally cycling women of the same age (28.3 +/- 1.14 years).InterventionsIn women with endometriosis, six SC implants of the GnRH-a compound, 3.6 mg goserelin acetate depot,…
  2. 02HumanNon-randomized trialSafety outcome

    In women with endometriosis, reduced lumbar bone mineral density remained evident 6 months after goserelin withdrawal.

    In plain wordsLumbar bone density remained reduced 6 months after goserelin withdrawal in women with endometriosis.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar bone mineral density after withdrawal
    Study

    n = 28

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days, six implants · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    This reduction was still evident 6 months after GnRH-a interruption.
    3 context sentences
    Summary · context
    Lumbar bone mineral density values significantly decreased after 6 months of GnRH-a treatment.
    Summary · context
    Controlled clinical study in volunteer women.
    Summary · context
    Twenty-eight women (mean age +/- SE 81.1 +/- 0.99 years) with endometriosis diagnosed by laparoscopy and 25 healthy, normally cycling women of the same age (28.3 +/- 1.14 years).InterventionsIn women with endometriosis, six SC implants of the GnRH-a compound, 3.6 mg goserelin acetate depot,…
  3. 03HumanNon-randomized trialSafety outcome

    In women with endometriosis, the lumbar bone mineral density reduction disappeared 24 months after goserelin withdrawal, and values were superimposable (+/- 0.4 percent) to pretreatment values.

    In plain wordsLumbar bone density returned to pretreatment values 24 months after goserelin withdrawal in women with endometriosis.

    Peptide
    Goserelin
    Outcome
    Direction not reportedLumbar bone mineral density recovery
    Study

    n = 28

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days, six implants · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Deviation from pretreatment lumbar bone mineral density at 24 months after withdrawal
    ≈ 0.4 percent
    +/- as reported

    Source sentences

    Summary
    However, 24 months after treatment withdrawal, bone mineral density reduction disappeared and bone mineral density values were completely superimposable (+/- O.4 percent) to those observed before treatment.
    2 context sentences
    Summary · context
    Controlled clinical study in volunteer women.
    Summary · context
    Twenty-eight women (mean age +/- SE 81.1 +/- 0.99 years) with endometriosis diagnosed by laparoscopy and 25 healthy, normally cycling women of the same age (28.3 +/- 1.14 years).InterventionsIn women with endometriosis, six SC implants of the GnRH-a compound, 3.6 mg goserelin acetate depot,…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04203212

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

424 General Military Hospitaln = 411 Oct 2019 to 31 Dec 2020

Endometriosis · Bone Density · Muscle · Bone Metabolism

Trial pageClinicalTrials.govUpdated 12 Jan 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.